Ernexa Therapeutics Inc.

NASDAQ: ERNA · Real-Time Price · USD
1.25
0.07 (5.93%)
At close: Sep 16, 2025, 3:59 PM
1.25
0.00%
After-hours: Sep 16, 2025, 04:10 PM EDT

Ernexa Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
n/a n/a 1K 487K 47K 47K 17K 51K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost of Revenue
55K 69K -541K -60K 95K 602K 547K 120K 63K 62K 86K 121K 152K 138K 123.4K 123.42K 117.28K 94.9K
Gross Profit
-55K -69K 542K 547K -48K -555K -530K -69K -63K -62K -86K -121K -152K -138K -123.4K -123.42K -117.28K -94.9K
Operating Income
-2.5M -2.73M -2.7M -2.26M -4.93M -5.79M -5.76M -5.5M -4.55M -5.32M -4.74M -8.3M -13.88M -6.3M -9.11M -86.33M -10.01M -8.1M
Interest Income
n/a n/a 249K n/a n/a n/a n/a n/a 24K 2K n/a n/a n/a n/a n/a n/a n/a n/a
Pretax Income
-3.14M -8.19M -5.75M -26.59M -5.53M -6.64M -6.16M -5.6M -4.5M -5.41M -4.45M -7.31M -3.4M -9.38M -8.46M -86.06M -10.09M -17.7M
Net Income
-3.15M -8.2M -5.76M -26.6M -5.53M -6.65M -6.15M -5.59M -4.51M -5.42M -4.49M -7.32M 7.08M -12.45M -8.46M -86.06M -10.09M -17.7M
Selling & General & Admin
1.36M 1.42M 1.54M 3.38M 3.9M 3.77M 4.03M 3.98M 2.51M 3.59M 2.77M 3.19M 5.43M 4.24M 4.35M 4.26M 4.62M 1.64M
Research & Development
1.14M 1.31M 1.16M 1M 987K 1.46M 1.21M 1.46M 1.58M 1.67M 1.96M 4.96M 1.69M 1.78M 4.18M 1.47M 5.39M 1.52M
Other Expenses
-55K -69K n/a -1.58M n/a n/a n/a n/a -280K 50K -5K n/a -1K -1.14M 647K -12.63K -22.19K -2.56K
Operating Expenses
2.45M 2.66M 2.7M 2.81M 4.88M 5.23M 5.24M 5.44M 4.09M 5.32M 4.74M 8.15M 7.12M 6.03M 8.54M 5.72M 10.01M 3.16M
Interest Expense
n/a 5K 3.48M 1.69M 797K 786K 388K 114K n/a 105K 6K 10K 13K 1K 18.03K 20.21K 22K 14K
Selling & Marketing Expenses
n/a n/a n/a n/a n/a -541K -481K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
2.5M 2.73M 2.7M 2.75M 4.98M 5.83M 5.78M 5.56M 4.09M 5.32M 4.74M 8.15M 7.12M 6.03M 8.54M 5.72M 10.01M 3.16M
Income Tax Expense
-3K 8K 11K 12K 3K 4K -4K -8K 4K 5K 40K 5K -10.48M 3.08M 5K 7.58K -67.28K 14.54M
Shares Outstanding (Basic)
5.18M 53.36M 51.39M 5.41M 5.41M 5.41M 5.41M 5.41M 5.3M 5.13M 4.4M 2.94M 2.94M 2.68M 2.6M 2.53M 2.12M 1.39M
Shares Outstanding (Diluted)
5.18M 53.36M 51.39M 5.41M 5.41M 5.41M 5.41M 5.41M 5.3M 5.13M 4.4M 2.94M 2.94M 2.68M 2.6M 2.53M 2.12M 1.39M
EPS (Basic)
-0.61 -0.15 -0.42 -4.92 -1.02 -1.23 -1.14 -1.03 -0.85 -1.06 -1.02 -2.49 2.41 -4.65 -3.25 -34.05 -4.75 -12.74
EPS (Diluted)
-0.61 -0.15 -0.42 -4.92 -1.02 -1.23 -1.14 -1.03 -0.85 -1.06 -1.02 -2.49 2.41 -4.64 -3.25 -34.05 -4.75 -12.74
EBITDA
-2.5M -2.66M -2.2M -24.45M -4.15M -5.32M -5.69M -4.97M -4.03M -5.25M -4.36M -7.18M -3.23M -9.24M -8.32M -85.93M -9.97M -17.61M
EBIT
-3.14M -2.73M -2.27M -24.91M -4.73M -5.86M -6.17M -5.49M -4.09M -5.32M -4.44M -7.3M -3.38M -9.37M -8.44M -85.97M -10.06M -18.51M
Depreciation & Amortization
55K 69K 68K 451K 578K 541K 481K 517K 63K 62K 86K 121K 152K 138K 123.4K 123.42K 117.28K 94.9K